Escherichia coli cells can act as an analog calculator, sensing chemicals over a dynamic range of four orders of magnitude while performing mathematical calculations, according to synthetic biologists Ramiz Daniel, Jacob R. Rubens, Rahul Sarpeshkar, and Timothy K. Lu from the Massachusetts Institute of Technology (MIT) in Cambridge, Mass. These cell-based analog circuits could prove useful for controlling protein or drug and other fıne chemical production in microbes, they say. Details appear May 15, 2013 in Nature (doi:10.1038/nature12148).
The assembly of plasmids containing analog circuits and based on three transcription factors is made by harnessing DNA cloning techniques that are used widely in synthetic biology, according to Sarpeshkar. "Bacterial cells that have been transformed by the plasmids are cultured with molecular inputs of varying and controlled concentrations," he says. "Optical fluorescence measurements that represent the outputs of the circuits in the cells are made on a fluorescence activated cell sorting (FACS) machine. These output measurements along with measurements of the molecular input concentrations then provide an input-output transfer function." This MIT research is a "breakthrough," says synthetic biologist Herbert Sauro at the University of Washington in Seattle. "First it shows that analog computations can be done reliably using cellular components," he says. "Secondly it reminds us that there is another approach to computation other than digital, [which] perhaps is the most important message. Researchers have implemented basic digital computations in cells, but these don't scale very well. To my knowledge, this is the fırst example of calculations done in a cell using an analog approach, [which] is much more scalable and less of a metabolic burden on a cell than trying to engineer digital gates."
Analog circuitry might prove useful in biotechnology. For example, bacterial cell-based analog circuits might be used to monitor how fast a nutrient concentration is dropping to estimate how long it will last-an important calculation within many metabolic engineering schemes, according to Sauro. Another use might involve measuring environmental cues, and setting the system to turn on or off genes in response to those cues, perhaps using synthetic biology to respond to complex signals from microbial communities, he says. "Instead of turning genes on or off, we could partially turn genes on, redirecting fluxes in much more subtle ways. We could also monitor the internal state of the cell much more precisely and only when certain conditions are met should we activate our engineered metabolic pathway."
The big message is not so much about potential applications as about moving from digital to analog computations within living cells, according to Sarpeshkar and his collaborators. "Analog computation promises to scale signifıcantly better in natural cells because it is like what they already do," he says. "In fact, we are exploiting similarities between log-domain analog electronics in transistors and log-domain ana-log computation in cells to great advantage." Barry E. DiGregorio is a freelance writer in Middleport, N.Y.
RESEARCH ADVANCES

Harnessing Microbes To Help Control Foodborne Pathogens Shannon Weiman
Bacteriophage and some types of bacteria offer an alternate means for controlling foodborne pathogens at various stages of food production and processing, according to several researchers who spoke during several sessions of the 2013 ASM General Meeting, held in Denver last May. Some of them described how native bacteria can outcompete pathogenic strains on plants during growth and harvest, while others outlined how bacteriophage can kill pathogens on plants before they are harvested or later during food processing.
"With 1 in 100 hospitalizations attributed to foodborne pathogens . . . novel, ecologically sound intervention strategies are essential," says Jie Zheng, who leads a group investigating Salmonella outbreaks at the Food and Drug Agency (FDA) Center for Food Safety and Applied Nutrition. Sarah Allard presented the group's work during the poster session "Foodborne Pathogens-Control."
Zheng's group sampled soils from Virginia, where Salmonella enterica is a frequent source of foodborne diseases, and identifıed 17 bacterial strains that inhibit Salmonella growth. One Bacillus strain, designated TS-15, is active in protecting tomatoes, a common vehicle for S. enterica. "TS-15 yielded a pre-cipitous fıve-log drop in Salmonella cell inoculum, completely preventing pathogen recovery on fruit surfaces," Allard says. Applying TS-15 to plants and soil reduces the pathogen, particularly during transplantation when seedlings can internalize Salmonella through injured roots. Several Bacillus species also are active against Escherichia coli, Shigella, Enterobacter, Listeria, and Staphylococcus aureus, and thus might prove useful in curbing these pathogens on leafy greens, peppers, meats, and cheeses, Zheng says.
Bacteriophages are abundant and target virtually all varieties of bacteria but are harmless to plants, animals, and humans. For example, phage that infect E. coli O157:H7 may prevent this pathogen from contaminating alfalfa sprouts and other leafy greens, according to Dandan Zhang of Purdue University in West Lafayette, Ind. In an agar-based model system, he found that T4 phage, applied as a seed coating prior to germination, can protect sprouting seedlings both inside and out.
Phage also might be used to control foodborne pathogens in milk and milk products, according to Lynn Haddad of the Université Laval in Quebec City, Quebec, Canada, who spoke during the symposium "Fermented Foods and Beverages: a Flavorful Blend of Culinary Tradition and Microbial Terroir." She isolated a strain of phage from raw milk that targets S. aureus, but spares other bacteria that impart flavor and texture to cheeses. The phage, LH1-MUT, proved stable through cheese making and for at least one month after processing. Its stability means this phage can be added to raw milk as cheese making begins to prevent growth of staphylococcal bacteria or their production of enterotoxin, which can persist after the bacteria themselves are degraded.
Separately several years ago, FDA approved phage to target Listeria bacteria in cheeses and meats. However, high temperatures inactivate that phage, restricting its use to the later stages of food production-in the case of cheeses, to the ripening stage-and to food storage after processing.
Shannon Weiman is a freelance writer in San Francisco, Calif.
MINITOPIC
Cautions Raised over Using Antibiotics as a Nutrition Supplement
Investigators urge careful study before adding antibiotics routinely to food regimens used for treating children with severe malnutrition. "While our team did not object to adding antibiotics to ready-to-use therapeutic foods administered in a supervised setting, which is current practice, we are, however, worried that extending this practice to a community setting could increase selective pressure on bacteria, leading to increased antibiotic resistance," says Stuart Levy of Tufts University Medical School in Boston, Mass., who heads a coalition of microbiologists and other experts belonging to the Alliance for the Prudent Use of Antibiotics (APUA). Meanwhile, epidemiologist Emilia H. Koumans and her collaborators at the Centers for Disease Control and Prevention (CDC) in Atlanta, Ga., say that the HIV status as well as other drug treatments of the children in Malawi who received antibiotic supplements while being treated for malnutrition "may confound the interpretation of the trial findings." Letters from the APUA and CDC groups appear June 20, 2013 in the New England Journal of Medicine (N. Engl. J. Med., doi: 10.1056/NEJMc 13044070. That clinical trial involving children in Malawi was conducted by Mark J. Manary of Washington University in St. Louis, Mo., and his collaborators. Adding "antibiotics to therapeutic regimens for uncomplicated severe acute malnutrition was associated with a significant improvement in recovery and mortality rates," they concluded in their report earlier this year. Details of that clinical trial appeared January 31, 2013 in the New England Journal of Medicine (doi: 10.1056/NEJMoa1202851).
Phages may help protect consumers from pathogenic E. coli strains that can contaminate alfalfa sprouts and other leafy greens (Photo © Tara Oldfield/iStockphoto.)
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RESEARCH ADVANCES
Sepsis Drug Shows Promise against Influenza in Rodents Carol Potera
Eritoran, a candidate drug developed by Eisai Inc. of Japan for treating sepsis, unexpectedly shows promise as a treatment for influenza when tested in rodents, according to Stefanie N. Vogel at the University of Maryland, Baltimore, and her collaborators. "For years people have focused on attacking the influenza virus," she says. "Our data show that you can get remarkable results by focusing on the host response rather than the virus." Details appeared online May 23, 2013 in Nature (doi:10. 1038/nature12118).
Earlier, Vogel learned that Toll-like receptor 4 (TLR4) knockout mice resist influenza infections. Eritoran is a synthetic antagonist of lipid A, and acts by preventing lipopolysaccharide (LPS) from binding to the mammalian MD2-TLR4 receptor complex. On its own, LPS, or endotoxin, is a major component of the outer membrane of many gram-negative bacteria, and its presence in mammalian hosts can trigger inflammatory illnesses or, more acutely, sepsis in the blood.
From her observations of how TLR4 knockout mice respond to influenza and her knowledge of eritoran's mode of action, Vogel and her collaborators decided to test whether eritoran can prevent influenza-induced deaths in mice. After animals were infected with the mouse-adapted influenza strain called PR8 and then treated with eritoran two days later, 90% of them survived. In contrast, only 10% of mice survived infections with that viral strain and follow-up treatment with a placebo. Those treatments with eritoran protect the influenza-infected mice against acute inflammatory lung damage, while also lowering viral titers and levels of cytokines such as interferon. Eritoran treatments similarly protect cotton rats that are infected with human influenza strain H3N2, she says.
"Eritoran could be repositioned as an intravenous drug to treat severe influenza infections in hospitalized patients," says Steven Opal of Brown University in Providence, R.I. Opal led the phase 3 clinical trial of eritoran for sepsis, whose fındings appeared in the March 20, 2013 Journal of the American Medical Association (doi:10.1001 /jama.2013.2194). In the clinical trial, eritoran performed no better than a placebo, prompting Eisai in 2011 to drop plans to pursue marketing authorization of eritoran for treating sepsis patients in the United States, Europe, or Japan.
Influenza patients could benefıt from intravenous eritoran, in particular those with primary influenza pneumonia caused by highly virulent avian influenza H5N1, or avian influenza H7N9, which has no current vaccine, Opal continues. In the phase 3 trial, he adds, "A one-week course of eritoran was given in very high doses to very sick patients with sepsis, and its safety record is excellent."
"It may help that very clinically ill people with sepsis were safely given eritoran without signifıcant negative effects," Vogel says. "Hopefully, eritoran
MINITOPIC
Metals Play Distinct Roles in Several Antimicrobial Schemes
Various research groups are investigating how metals, including gold, silver, and copper, can augment strategies for combatting pathogens. Recent examples include:
• Gold nanoparticles, shaped and sized to resemble the respiratory syncytial virus (RSV) and coated with the RSV F protein, are adept at stimulating human dendritic cells-making these particles promising as a candidate vaccine to protect against RSV, according to James Crowe of Vanderbilt University in Nashville, Tenn., and his collaborators. Details appeared June 26, 2013 in Nanotechnology (http://iopscience.iop.org/0957-4484/24/29/295102).
• A silver-based nanoparticle is part of a probe for measuring blood for early evidence of microbial infections; such nanoparticles are used in conjunction with lasers to detect surface-enhanced Raman scattering (SERS), according to Tuan Vo-Dinh of Duke University in Durham, N.C., and his collaborators. Details appeared July 5, 2013 in Analytica Chimica Acta (doi:10.1016/j.aca.2013.05 .017).
• Combining silver with antibiotics can enhance their effectiveness, in part by disrupting cellular metabolism and the balance of iron in target bacterial cells, and also may expand the range of bacteria against which particular antibiotics act, according to James Collins of Boston University in Boston, Mass., and his collaborators. Details appeared June 19, 2013 in Science Translational Medicine (doi: 10.1126/scitranslmed.3006276). will fınd a niche somewhere else in the treatment of human disease."
Carol Potera is a freelance writer in Great Falls, Mont.
RESEARCH ADVANCES
Anti-Inflammatory Drug Has Activity Blocking Virulence Factors David C. Holzman
In a quest for alternatives to antibiotics, Menachem Shoham of Case Western Reserve University in Cleveland, Ohio, and his collaborators identifıed-and repurposed-the anti-inflammatory agent diflunisal to target a key transcriptional regulator that controls expression of virulence genes in methicillin-resistant Staphylococcus aureus (MRSA), without killing the pathogen or inhibiting its growth. This approach, called anti-virulence therapy, could prevent this pathogen from causing disease without generating antibiotic resistance. "Since all bacteria employ quorum sensing mechanisms, this approach is in principle valid for all bacterial pathogens," he says. Details appeared May 20, 2013 in Antimicrobial Agents and Chemotherapy (doi:10 .1128/AAC.00269 -13).
Without a crystal structure for the regulatory domain of the transcription regulator, AgrA, the investigators used information describing the structure of a similar protein to compute a likely structure for AgrA. They then screened 90,000 low-molecular-weight compounds by docking each into a virtual binding pocket of the target protein.
Among the 107 top-scoring compounds in vitro, they identifıed diflunisal, a nonsteroidal anti-inflammatory agent that offıcials of the Food and Drug Administration licensed for general use more than four decades ago.
"The study is intriguing as it shows that we may fınd valuable new treatment options in our large libraries of existing compounds," says Hanne Ingmer of the University of Copenhagen in Denmark, who was not involved in the research.
"Targeting global virulence regulators is often problematic, because they don't regulate all virulence determinants in the same fashion," says Michael Otto of the National Institute of Allergy and Infectious Disease at the National Institutes of Health (NIH) in Bethesda, Md., who praises Shoham's approach. "While inhibiting Agr-as the drugs in the present paper doleads to decreased expression of toxins, this also leads to upregulation of surface proteins, such as protein Awhich are necessary for other virulence aspects of S. aureus." Examples, he says, include tissue attachment, biofılm formation, and evasion of antibodybased host defense. Additionally, he says, "Whether the in vitro effect translates to real inhibition of infection, at least in animals, is not clear."
Although diflunisal awaits testing as a virulence blocker in animal studies, other antivirulence agents that target single virulence factors appear to be effective when tested in animals at protecting them in some cases or reducing the severity of MRSA in other cases, according to Shoham.
Anti-virulence approaches need to be tested for unintended consequences, "especially since targeting the accessory gene regulator function is associated with increased expression of other potent S. aureus virulence factors," says Juliane Bubeck Wardenburg of the University of Chicago in Chicago, Ill. Those other factors include
MINITOPIC
Images, Synthesis of Ribosome; Insights, Target Improvement
Recent efforts to better understand ribosomes, the seat of protein synthesis, offer insights not only into how they function but also how to block those functions with antibiotics or other agents when necessary. Examples include:
• The 54 proteins and 3 synthetic RNA molecules from Escherichia coli ribosomes can now be assembled in vitro to transcribe proteins from messenger RNA (mRNA) molecules, providing a potential new means for developing novel antibiotics to target ribosomes, according to Michael Jewett of Northwestern University in Evanston, Ill., George Church of Harvard University in Cambridge, Mass., and their collaborators. Details appeared June 25, 2013 in Molecular Systems Biology (doi:10.1038/msb.2013.31).
• New images help to explain how elongation factor G acts like a ratchet, preventing ribosomes from slipping backward while moving along mRNA molecules and synthesizing proteins, according to Arto Pulk of the University of California, Berkeley, and Jamie Cate at nearby Lawrence Berkeley Laboratory. Details appeared June 28, 2013 in Science (doi: 10.1126/science.1235970). Closely related articles on bacterial ribosomes can be found in the same issue of Science.
• Two promising experimental inhibitors of prions that bind to ribosomes apparently target its protein-folding activity, identifying this function as a potential route to treating Creutzfeldt-Jakob disease in humans, scrapie in sheep, or similar prion-associated diseases, according to Suparna Sanyal of Uppsala University in Uppsala, Sweden, and her collaborators. Details appeared June 28, 2013 in the Journal of Biological Chemistry (doi: 10.1074/jbc.M113 .466748).
staphylococcal protein A, which modulates adaptive host immunity, she points out.
David C. Holzman is the Microbe Journal Highlights Editor.
RESEARCH ADVANCES
Exploring Antibiotic Resistance Uncovers Host-Pathogen Quirks Jeffrey L. Fox
Antibiotic resistance is not so simple a bug-drug phenomenon. In some cases, the host immune system or other factors impinge on drug treatments in ways that change their effectiveness in treating patients, the development of resistance, and strategies for combating resistance or for developing new drugs. Here are some highlights from the 2013 ASM General Meeting (GM), held in Denver, Colo., last May. Some tuberculosis (TB) patients struggle with Mycobacterium tuberculosis infections while being treated with antibiotics and then sometimes are "blamed for failing therapy when taking drugs for which their bug is susceptible," says Sarah Fortune of the Harvard School of Public Health in Boston, who spoke during the GM plenary session, "Bedside to Bench: Microbiology in the Clinics." Despite M. tuberculosis supposedly having a low capacity for genetic diversity and, presumably, for developing resistance, "genomic sequencing suggests the picture is more complicated," she says.
Some of that complexity resides in the numbers of drug-resistant mutations that can occur in M. tuberculosis, a pathogen that replicates slowly and which may become latent during infections, Fortune continues. "Contrary to expectations, this microbe acquires mutations at the same rate regardless of the status of an infection, latent versus active, and at the same rate as when growing in culture," she says. "This is really surprising and goes against dogma."
Another surprise is that the bacterial burden in patients (or in experimentally infected macaques) remains "stunningly" constant, even during antibiotic treatment because the bacterial "'corpses' hang around for a long time," Fortune says. Cumulative mutations that are responsible for drug resistance reflect time-dependent damage to DNA, not changes in replication rates between active and latent bacteria. An important upshot is that very early diagnosis, when the bacterial burden is low, followed by earlier and more intense treatment of TB patients could help to slow the rate of multidrug resistance (MDR) development and thus might ease the challenges in treating MDR TB on a global scale.
"Treatment failure is not due only to drug resistance," says Bruce Levin of Emory University in Atlanta, Ga., referring more generally to infectious diseases, when he spoke during the GM plenary, "Translating Knowledge of Bacterial Pathogenesis into Next Generation Antimicrobials." One problem stems from relying too heavily on minimal inhibitory concentration (MIC)based measurements when assigning antibiotics for treating patients, Levin asserts. Although "easily measured" and thus well liked, MICs usher in "tremendous bias," he says. "How many antimicrobial drugs are we not using because they fail this test? But what will replace it?"
One contender is the Hill function, an independent but admittedly messier measure that entails following how long it takes for antibiotics to kill particular bacterial pathogens, according to Levin, a proponent of this alternative to MICs for the past decade. Although "MICs are here to stay," he says, Hill functions offer an additional set of insights, particularly when evaluating antimicrobial drug candidates that MIC testing might rule out or for situations such as biofılms or persister cells where MIC-based choices also may fall short.
With Pierre Ankomah, Levin is extending this modeling approach, attempting to account also for host-immune responses as they contribute to antibiotic failure or success. Such modeling suggests that treating patients with high doses of such drugs decreases the immunopathologic effects of some infections, Levin says, sharing newfound disquietude. "We're now defenders of orthodoxy-promoting high-dose chemotherapy." Jeffrey L. Fox is the Microbe Current Topics and Features Editor.
MINITOPIC
Salmonella Toxin May Account for Its unusual Lethality
Typhoid fever is so lethal in large part because Salmonella enterica serovar Typhi produces a toxin composed of two toxic subunits that can cause in mice many of the symptoms associated with infection by this bacterial pathogen, according to Jorge Galan of Yale University in New Haven, Conn., and his collaborators. One of those protein toxin subunits is a DNase that inflicts DNA damage and induces cell-cycle arrest, while the other subunit, which resembles the pertussis toxin, has ADP-ribosyl transferase activity. When mice are injected with the intact toxin, they become lethargic and die, while other tests indicate that their circulating immune cells become severely depleted. "What makes this so exciting for us is that vaccines and therapeutics that target toxins have an excellent track record of success," Galan says. Details appeared July 10, 2013 in Nature (doi:10.1038/nature12291).
RESEARCH ADVANCES
By Boosting Particular Marine Microbes, Climate Change Threatens Health Shannon Weiman
Increased temperatures and droughts associated with global climate change promote growth of particular aquatic microbes that can threaten human health as well as marine life, according to several researchers who spoke during the special interest symposium, "Oceans and Human Health: The Microbiological Perspective," at the 2013 ASM General Meeting, held in Denver, Colo., last May. In particular, such conditions help vibrios and cyanobacteria to expand their geographic ranges, disrupt local ecosystems, and put humans and other species at increased risk.
Climate change is enabling pathogenic Vibrio species to expand their range, extending their capacity to cause disease in humans and marine organisms, according to Erin Lipp of the University of Georgia, Athens. "Vibrios are fırst responders to new carbon and nutrient sources," she says. Elevated temperatures also encourage this expansion, particularly at 15°C and higher, at which vibrios replicate faster than other competing microbial species. These factors enable Vibrio species to invade major seafood-producing regions, such as Prince William Sound and the Chesapeake Bay.
Higher temperatures also induce Vibrio strains to produce factors that enable them to resist natural antibiotics released by coral species, according to Pam Morris of the University of South Carolina, Columbia. "A greater number of antibiotic resistance proteins were detected at 27°C than at 24°C, allowing Vibrio to resist the antimicrobials produced by the coral's normal bacterial community," she says. At least 136 Vibrio virulence factors are upregulated, and they are involved not only in antimicrobial resistance but also motility, host degradation, secretion, and transcriptional regulation, enabling these strains to out-compete their neighbors, she says.
Cyanobacterial blooms also are increasing in frequency and geographic distribution, expanding into temperate regions and threatening freshwater resources, according to Hans Paerl of the University of North Carolina in Moorhead City. "Blooms now threaten the ecological integrity and sustainability of some of the world's largest and most resourceful water bodies, including Lake Victoria in Africa, Lake Erie in North America, Lake Taihu in China, and the Baltic Sea in Europe," he says. "Some toxin-producing cyanobacteria appear to be particularly successful at exploiting climatic change."
Cyanobacteria require less nutrient input and grow better at temperatures higher than 25°C than do other phytoplankton, Paerl continues. Buoyant cyanobacteria create a feedback mechanism, increasing temperatures at the surface by blocking light, oxygen, and carbon dioxide from reaching phytoplankton below. These surface blooms smother aquatic plants, disrupting habitats for marine invertebrates and fısh.
"Protracted droughts also benefıt cyanobacteria," Paerl says. If water sources dry up, cyanobacteria can lay dormant as cysts for years. "Summer droughts, rising sea levels, increased withdrawal of fresh water for agricultural use, and application of road salt have led to rising lake salinities in many regions, favoring cyanobacteria, which are more salt tolerant than freshwater phytoplankton," he says. Higher salinity also leads cyanobacteria to produce more toxins, he adds. These toxins persist long after blooms subside, continuing to harm both aquatic ecosystems and terrestrial animals that use contaminated drinking sources. In humans these toxins cause potentially fatal liver, digestive, neurological, and skin diseases, including "Palm Island mystery disease," a severe hepatitis-like illness that fırst occurred in 1979 on Palm Island, Australia. gene regulation occurs in genes regulated by [polycomb repressor complex 2 (PRC2)] activity [including EZH2]," according to the paper. The investigators note that EZH2 overexpression "is associated with a worse prognosis in prostate, breast, endometrial, and melanoma tumors." The bioinformatics technique used in this research can be used to predict aggressiveness of these and other cancers, says Benevolenskaya. (A. Jene-Sanz, R. Varaljai, A.V. Vilkova, G. F. Khramtsova, A. I. Khramtsov, O. I. Olopade, N. Lopez-Bigas, and E. V. Benevolenskaya. 2013 . Expression of polycomb targets predicts breast cancer prognosis. Mol. Cell. Biol. Online ahead of print 7 May 2013; doi:10.1128/MCB.00426 -13.) 
CLINICAL AND VACCINE IMMUNOLOGY
Microneedles Prove Advantageous for Influenza Vaccine
Microneedles are far less painful for influenza vaccination than ordinary hypodermic needles, as they are only seventenths of a millimeter in length, and the volume of vaccination fluid-a source of that pain-is minuscule. Now Sang-Moo Kang of Georgia State University, et al. show that "Microneedle vaccination of mice in the skin induced 100% protection against lethal challenge infection with influenza A/PR/8/34 virus 14 months after a single vaccine dose," according to the report. In pre-vious studies, this group showed that "microneedles provided higher short-term effıcacy than did intramuscular immunization," the researchers write. Kang notes that "this method can [also] induce higher levels of IgG2a antibodies as well as rapid recall immune responses, including HAI titers, neutralizing activities, mucosal antibodies in lungs, and antibody-secreting cells following lethal challenge infection. Our previous study showed that microneedle vaccination induced higher levels of antibody-secreting cells in spleen and bone marrow compared to intramuscular vaccination." (F.-S. Quan, Y.-C. Kim, J.-M. Song, H. S. Hwang, R. W. Compans, M. R. Prausnitz, and S.-M. Kang. 2013 . Long-term protective immunity from an influenza virus-like particle vaccine administered with a microneedle patch. Clin. Vacc. Immunol. Online ahead of print 17 July 2013; doi:10.1128 /CVI.00251-13.) 
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
FDA "Reboot" Brings Hope For New Antibiotics Development
It is no secret that antibiotic resistance has been rising dangerously, and that the pipeline for new antibiotics has all but dried up. The fault, David Shlaes, et al. write in a Commentary in Antimicrobial Agents and Chemotherapy, lies partly with the U.S. Food and Drug Administration (FDA). Therefore, the FDA announced in May 2012 a "reboot" of antibiotic development. But except for a recent guidance document on antibacterial therapies for patients with unmet needs, details have yet to be released.
The problem began with a rethinking of clinical trials, catalyzed by "radical skeptic statisticians" who doubted antibiotics' effectiveness, says coauthor Brad Spellberg, of LA BioMed at Harbor-UCLA Medical School, Los Angeles. It was aggravated in 2006, when a recently approved drug, telithromycin, was found to cause a very rare but lifethreatening liver toxicity. Then, new regulations rendered clinical trials virtually impossible to conduct, and prohibitively expensive, the former partly due to barring taking antibiotics prior to enrollment, a situation that would have forced desperately ill patients to go without during the six hours' average time it takes to enroll; the latter due to changes in statistical methods that more than doubled the numbers of patients needed, says Shlaes. The low return on investment with antibiotics aggravated the cost problem. But the FDA is now working to address these problems, says Shlaes.
